Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy Roy

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
JPEN. Journal of Parenteral and Enteral Nutrition|September 25, 2014
Pain and Anxiety Experienced by Patients Following Placement of a Percutaneous Endoscopic GastrostomyPhilip Oppong, Narrie Pitts, Vicky Chudleigh, et al.
Pediatric Quality & Safety|January 12, 2022
A Quality Improvement Project to Delay Umbilical Cord Clamping TimeAmanda N Pauley, Amy Roy, Yaslam Balfaqih, et al.
Population Health Management|March 25, 2021
An Integrated Mobile Acute Care Service Enhances ValueAndrew W Artenstein, Nathan Stanaway, Amy Roy, et al.
Journal of Anxiety Disorders|August 12, 2017
Factor structure of the intolerance of uncertainty scale for childrenDanielle Cornacchio, Amanda L Sanchez, Stefany Coxe, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trialGiuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
BMJ Open|September 3, 2020
Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesotheliomaEric Lim, Liz Darlison, John Edwards, et al.
The Lancet. Respiratory Medicine|May 13, 2024
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trialEric Lim, David Waller, Kelvin Lau, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
JPEN. Journal of Parenteral and Enteral Nutrition|September 25, 2014
Pain and Anxiety Experienced by Patients Following Placement of a Percutaneous Endoscopic GastrostomyPhilip Oppong, Narrie Pitts, Vicky Chudleigh, et al.
Pediatric Quality & Safety|January 12, 2022
A Quality Improvement Project to Delay Umbilical Cord Clamping TimeAmanda N Pauley, Amy Roy, Yaslam Balfaqih, et al.
Population Health Management|March 25, 2021
An Integrated Mobile Acute Care Service Enhances ValueAndrew W Artenstein, Nathan Stanaway, Amy Roy, et al.
Journal of Anxiety Disorders|August 12, 2017
Factor structure of the intolerance of uncertainty scale for childrenDanielle Cornacchio, Amanda L Sanchez, Stefany Coxe, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trialGiuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
BMJ Open|September 3, 2020
Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesotheliomaEric Lim, Liz Darlison, John Edwards, et al.
The Lancet. Respiratory Medicine|May 13, 2024
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trialEric Lim, David Waller, Kelvin Lau, et al.
Pageof 1